Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials

Journal of Affective Disorders

Volumn 201, Issue , 2016, Pages 116-123

  McIntyre, Roger S ^a   Weiller, Emmanuelle ^b   Zhang, Peter ^c   Weiss, Catherine ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b H LUNDBECK A S   (Denmark)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Adjunctive treatment; Anxious distress; Brexpiprazole; Major depressive disorder

Indexed keywords

ANTIDEPRESSANT AGENT; BREXPIPRAZOLE; HYDROCORTISONE; PLACEBO; DOPAMINE RECEPTOR STIMULATING AGENT; QUINOLONE DERIVATIVE; SEROTONIN RECEPTOR AFFECTING AGENT; THIOPHENE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AKATHISIA; ANXIETY DISORDER; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISTRESS SYNDROME; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DSM-5; FATIGUE; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; ANXIETY DISORDERS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOMOTOR AGITATION; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOMOTOR AGITATION; QUINOLONES; SEROTONIN AGENTS; THIOPHENES; TREATMENT OUTCOME;

EID: 84969217028     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2016.05.013     Document Type: Article

References (24)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders Fifth edition 2013 American Psychiatric Association Arlington, VA
2. American Psychiatric Association, 2000. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR).
3. B. Bandelow, M. Bauer, E. Vieta, N. El-Khalili, U. Gustafsson, W.R. Earley, and H. Eriksson Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline World J. Biol. Psychiatry 15 2014 155 166
4. G.M. Chandler, D.V. Iosifescu, M.H. Pollack, S.D. Tarqum, and M. Fava RESEARCH: validation of the Massachusetts general hospital antidepressant treatment history questionnaire (ATRQ) CNS Neurosci. Ther. 16 2010 322 325
5. M. Fava, J.E. Alpert, C.N. Carmin, S.R. Wisniewski, M.H. Trivedi, M.M. Biggs, K. Shores-Wilson, D. Morgan, T. Schwartz, G.K. Balasubramani, and A.J. Rush Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR∗D Psychol. Med. 34 2004 1299 1308
6. M. Fava, A.J. Rush, J.E. Alpert, G.K. Balasubramani, S.R. Wisniewski, C.N. Carmin, M.M. Biggs, S. Zisook, A. Leuchter, R. Howland, D. Warden, and M.H. Trivedi Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR∗D report Am. J. Psychiatry 2165 2008 342 351
7. T. Furukawa, D.L. Streiner, and L.T. Young Antidepressant plus benzodiazepine for major depression Cochrane Database Syst. Rev. 4 2000
8. W. Guy ECDEU Assessment Manual for Psychopharmacology 1976 National Institute Of Mental Health Rockville, MD 76 338
9. M. Hamilton A rating scale for depression J. Neurol. Neurosurg. Psychiatry 23 1960 56 62
10. D.F. Ionescu, M.J. Niciu, E.M. Richards, and C.A. Zarate Jr Pharmacologic treatment of dimensional anxious depression: a review Prim. Care Companion CNS Disord. 2014 2014 16 pii: PCC.13r01621
11. R.C. Kessler, C.B. Nelson, K.A. McGonagle, J. Liu, M. Swartz, and D.G. Blazer Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey Br. J. Psychiatry Suppl. 168 1996 17 30
12. K. Maeda, H. Sugino, H. Akazawa, N. Amada, J. Shimada, T. Futamura, H. Yamashita, N. Ito, R.D. McQuade, A. Mørk, A.L. Pehrson, M. Hentzer, V. Nielsen, C. Bundgaard, J. Arnt, T.B. Stensbøl, and T. Kikuchi Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator J. Pharm. Exp. Ther. 350 2014 589 604
13. S.A. Montgomery, and M. Åsberg A new depression scale designed to be sensitive to change Br. J. Psychiatry 134 1979 382 389
14. C.U. Pae, A. Forbes, and A.A. Patkar Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data CNS Drugs 25 2011 109 127
15. A.J. Rush, C.M. Gullion, M.R. Basco, R.B. Jarrett, and M.H. Trivedi The Inventory of Depressive Symptomatology (IDS): psychometric properties Psychol. Med. 26 1996 477 486
16. M. Sanford Quetiapine extended release: adjunctive treatment in major depressive disorder CNS Drugs 25 2011 803 813
17. D.V. Sheehan The Anxiety Disease 1983 Charles Scribner & Sons New York
18. M.E. Thase, M.H. Trivedi, J.C. Nelson, M. Fava, R. Swanink, Q.V. Tran, A. Pikalov, H. Yang, B.X. Carlson, R.N. Marcus, and R.M. Berman Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies Prim. Care Companion J. Clin. Psychiatry 10 2008 440 447
19. M.E. Thase, J.M. Youakim, A. Skuban, M. Hobart, C. Augustine, P. Zhang, R.D. McQuade, W.H. Carson, M. Nyilas, R. Sanchez, and H. Eriksson Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants J. Clin. Psychiatry 76 2015 1232 1240
20. M.E. Thase, J.M. Youakim, A. Skuban, M. Hobart, P. Zhang, R.D. McQuade, M. Nyilas, W.H. Carson, R. Sanchez, and H. Eriksson Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study J. Clin. Psychiatry 76 2015 1224 1231
21. M.H. Trivedi, M.E. Thase, M. Fava, C.J. Nelson, H. Yang, Y. Qi, Q.V. Tran, A. Pikalov, B.X. Carlson, R.N. Marcus, and R.M. Berman Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features J. Clin. Psychiatry 69 2008 1928 1936
22. K. Wiethoff, M. Bauer, T.C. Baghai, H.J. Möller, R. Fisher, D. Hollinde, J. Kiermeir, I. Hauth, G. Laux, J. Cordes, P. Brieger, K.T. Kronmüller, J. Zeiler, and M. Adli Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German algorithm project J. Clin. Psychiatry 71 2010 1047 1054
23. B.M. Wright, E.H. Eiland III, and R. Lorenz Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature Pharmacotherapy 33 2013 344 359
24. M. Zimmerman, I. Chelminski, D. Young, K. Dalrymple, E. Walsh, and L. Rosenstein A clinically useful self-report measure of the DSM-5 anxious distress specifier for major depressive disorder J. Clin. Psychiatry 75 2014 601 607